Canuck44, I think the R/S depends upon the share price at the time of the meeting with the AMEX.
The one big push I see in hype from the clinical trials. Regardless of how the trials come out, they will be hyped to the max. Some investors will think Onko Sure is the best test to ever come down the pike. If the share price gets high enough, you may not see that R/S.
The problem with the clincial trials is the company already knows how the test will perform. They have been working with the test for a year and in a conference call last year, they said it performed within the 5% FDA limit and no new FDA application would be needed.
We know from the previous FDA application that the specificity is not really 95% and the test errors 26% of the time when cancer is actually growing.
IMO, these trials will not do much at all to change the sales of Onko Sure. Onko Sure cannot be advertised to doctors to REPLACE CEA because the FDA will fine the company severely for violating the label. Doctors will not stick their necks on the chopping block and switch to Onko Sure because it opens them for malpractice suits.
I just don't see Onko Sure ever being successful to any extent. The company will eventually run out of gas and the CEO will have to find something else to replace his $750,000 salary.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
